Eric Chatelain

List of Publications by Year
in descending order

31 papers	1,929 citations	361413 20 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	2273 citing authors

#	Article	IF	Citations
1	In vitro and in vivo experimental models for drug screening and development for Chagas disease. Memorias Do Instituto Oswaldo Cruz, 2010, 105, 233-238.	1.6	278
2	Chagas Disease Drug Discovery: Toward a New Era. Journal of Biomolecular Screening, 2015, 20, 22-35.	2.6	227
3	Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Scientific Reports, 2014, 4, 4703.	3.3	161
4	Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging. Antimicrobial Agents and Chemotherapy, 2015, 59, 4653-4661.	3.2	124
5	An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages. PLoS Neglected Tropical Diseases, 2012, 6, e1671.	3.0	117
6	Chagas disease research and development: Is there light at the end of the tunnel?. Computational and Structural Biotechnology Journal, 2017, 15, 98-103.	4.1	111
7	Translational challenges of animal models in Chagas disease drug development: a review. Drug Design, Development and Therapy, 2015, 9, 4807.	4.3	96
8	Drug discovery and development for neglected diseases: the DNDi model. Drug Design, Development and Therapy, 2011, 5, 175.	4.3	82
9	Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Scientific Reports, 2016, 6, 35351.	3.3	72
10	Complexes of Trypanosoma cruzi Sterol 14Î±-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease. Journal of Biological Chemistry, 2013, 288, 31602-31615.	3.4	69
11	Phenotypic screening approaches for Chagas disease drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 141-153.	5.0	68
12	Analogues of Fenarimol Are Potent Inhibitors of Trypanosoma cruzi and Are Efficacious in a Murine Model of Chagas Disease. Journal of Medicinal Chemistry, 2012, 55, 4189-4204.	6.4	58
13	Antitrypanosomal Activity of Fexinidazole Metabolites, Potential New Drug Candidates for Chagas Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 4362-4370.	3.2	57
14	Pharmacological Characterization, Structural Studies, andIn VivoActivities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib. Antimicrobial Agents and Chemotherapy, 2012, 56, 4914-4921.	3.2	50
15	7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2017, 60, 4212-4233.	6.4	47
16	Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease. Journal of Medicinal Chemistry, 2013, 56, 10158-10170.	6.4	43
17	Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment. BMC Infectious Diseases, 2014, 14, 302.	2.9	42
18	Development of (6R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2018, 61, 2329-2352.	6.4	42

#	Article	IF	Citations
19	Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection. Tropical Medicine and Infectious Disease, 2019, 4, 82.	2.3	30
20	6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2583-2589.	2.2	26
21	Animal models of Chagas disease and their translational value to drug development. Expert Opinion on Drug Discovery, 2020, 15, 1381-1402.	5.0	23
22	Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 207-213.	2.2	22
23	The translational challenge in Chagas disease drug development. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	1.6	21
24	Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Future Medicinal Chemistry, 2013, 5, 1733-1752.	2.3	19
25	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both inÂvitro and inÂvivo trypanocidal efficacy. European Journal of Medicinal Chemistry, 2020, 207, 112849.	5.5	13
26	Novel Therapeutic Approaches for Neglected Infectious Diseases. Journal of Biomolecular Screening, 2015, 20, 3-5.	2.6	8
27	Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 13, 107-120.	3.4	8
28	Antileishmanial and antitrypanosomal drug identification. Emerging Topics in Life Sciences, 2017, 1, 613-620.	2.6	5
29	Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti-Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties. Antimicrobial Agents and Chemotherapy, 2015, 59, 3645-3647.	3.2	4
30	The unmet medical need for Trypanosoma cruzi-infected patients: Monitoring the disease status. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165628.	3.8	4
31	Reply to â€œDrug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugsâ€• Antimicrobial Agents and Chemotherapy, 2015, 59, 7925-7925.	3.2	2